Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D56AJO
|
|||
Drug Name |
SKB315
|
|||
Drug Type |
Antibody drug conjugate
|
|||
Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 1 | [1] | |
Company |
Klus Pharma
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Claudin-18 (CLDN18) | Target Info | . | [2] |
KEGG Pathway | Cell adhesion molecules (CAMs) | |||
Tight junction | ||||
Leukocyte transendothelial migration | ||||
Hepatitis C | ||||
NetPath Pathway | IL4 Signaling Pathway | |||
Reactome | Tight junction interactions |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT05367635) A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SKB315 for Injection in Patients With Advanced Solid Tumors Expressing Claudin18.2. U.S.National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of Klus Pharma |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.